DiscoverBase to Base Biotech
Base to Base Biotech
Claim Ownership

Base to Base Biotech

Author: Jim Cornall

Subscribed: 7Played: 23
Share

Description

The Base to Base Biotech podcast is a weekly look at what's happening in the world of biotech, with interviews with biotech leaders around the world.

Whether it's a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed.

The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall.

Base to Base is an Ayr Coastal Media Ltd production.

84 Episodes
Reverse
The conversations this week are both related to endometriosis: on developing a new diagnosis tool with San Francisco company Endometrics’ CEO and co-founder Yana Aznavour, and on the developing a treatment side, it’s a discussion with Swedish company Gesynta Pharma’s chief medical officer and VP of clinical development, Eva Johnsson.Times:03:23 Endometrics23:15 Gesynta PharmaEndometricsThe diagnostic gap in women’s health is not just a clinical failure—it is a systemic one. For conditions like endometriosis, patients currently face an average diagnostic delay of nearly a decade, often requiring invasive surgical procedures just to receive an answer.CEO and co-founder Yana Aznavour and her team at Endometrics are changing that narrative by unlocking the power of a biological resource that has been overlooked for decades: menstrual blood. By combining proprietary biobanking with advanced bioinformatics, the company has developed a non-invasive, at-home molecular diagnostic platform.What begins with a validated test for endometriosis is expanding into a broader frontier of gynaecologic oncology and precision medicine, converting complex biological signals into clear, actionable clinical tools.Backed by UC Berkeley SkyDeck and recognised by the NIH RADx ENDO Challenge, Aznavour, is bridging the gap between molecular biology and real-world patient impact.Gesynta PharmaGesynta Pharma is a clinical-stage biotech company developing an innovative treatment for endometriosis. Its lead programme, vipoglanstat, is a novel oral, non-hormonal and non-opioid treatment candidate intended for long-term use, designed to target pain, inflammation and lesion development through selective inhibition of mPGES-1.Preclinical studies have demonstrated strong and sustained pain relief, together with a 70% reduction in endometriotic lesions in an advanced disease model. Clinical studies have shown full target engagement, robust pharmacokinetics and a favourable safety and tolerability profile.Gesynta is backed by an experienced team with extensive drug development expertise, leading scientific and clinical advisors, and an international investor base spanning European life science and US women's health specialists.The company recently completed enrolment in NOVA, its phase 2 clinical proof-of-concept and dose-finding trial.To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [email protected]
This week, we have a conversation with Dylan Yeo, CEO and co-founder of Klona Biotech about 3D printing of regenerative implants, and we chat with Joana Correia, CEO, CSO, and co-founder of Exogenus Therapeutics, about a new consortium leading the way on secretomes.Times:03:28 Klona Biotech25:30 Exogenus TherapeuticsKlona BiotechKlona is developing the first bioprinting system specifically designed to print regenerative implants for fibrous human tissues.Its bioprinting system integrates in-house developed software, hardware, and material science to produce constructs that replicate the fibrous microarchitecture of structural tissues and the necessary strength and flexibility for their function.Its goal is to create the necessary manufacturing layer to 3D print whole human tissues on demand for grafts and transplants.Exogenus TherapeuticsThe ExoCordOA consortium recently launched a five-year, €13m project to advance extracellular vesicle-enriched secretome therapies towards clinical use, with an initial focus on osteoarthritis.Led by Exogenus Therapeutics, ExoCordOA brings together 10 organisations with complementary expertise across different disciplines. The consortium will support the development of a new secretome-based medicine for osteoarthritis and help build the foundations for Europe’s leadership in secretome-based therapeutics.A central objective is to advance Exogenus’ lead candidate, EXO-101, towards clinical validation as a potential disease-modifying treatment for osteoarthritis. The programme will support clinical development while also addressing key scientific, manufacturing, quality-control and regulatory challenges that currently limit the clinical translation of extracellular vesicle and secretome therapies. The consortium aims to resolve systemic bottlenecks by helping to develop more standardised approaches, robust analytical and potency assessment methods, and a clearer regulatory pathway for future secretome-based medicines.To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [email protected]
Times:03:22 Ona Therapeutics24:08 Actuate TherapeuticsThis week, we have a conversation with Valerie Vanhooren, CEO and co-founder of Ona Therapeutics about first-in-class ADCs for tackling tumours, and Daniel Schmitt, president and CEO of Actuate Therapeutics, about targeting multiple molecular pathways in cancer that are involved in promoting tumour growth.Ona TherapeuticsOna Therapeutics has reached an important milestone in its development, advancing as a clinical-stage company with its lead first-in-class ADC, ONA-255, now progressing through phase 1a clinical development. More than half of the planned patients have already been enrolled in the study.Alongside this, Ona has appointed oncologist and physician Aleix Prat as chief medical officer. Prat has worked closely with the company and played a key role in the identification and validation of the target underlying ONA-255.ONA-255 is a first-in-class ADC designed to target treatment-resistant tumour biology through a novel mechanism, with an initial focus on HR+/HER2-negative advanced breast cancer and gastric cancer. The programme represents an important milestone for Ona following its $86.6m series B financing earlier this year.The company continues to expand its ADC pipeline, with ONA-389 expected to enter the clinic in the second half of 2027ONA-418 is advancing a dual-linker, dual-payload approach designed to broaden the potential of Ona's ADC portfolio.Actuate TherapeuticsActuate Therapeutics is developing elraglusib, an investigational GSK-3β inhibitor that targets several pathways involved in tumour growth and drug resistance while also modulating anti-tumour immunity.In metastatic pancreatic cancer, randomised phase 2 results published in Nature Medicine showed that adding elraglusib to standard chemotherapy reduced the risk of death by 38% and roughly doubled 12-month survival. Since then, Actuate has secured FDA clearance for a phase 1/2 study of an oral tablet formulation and is working with both the FDA and EMA on a potential registrational study.The company recently shared new preclinical data from its work with the Mayo Clinic and Northwestern University showing synergy with Revolution Medicines' RAS inhibitors zoldonrasib and daraxonrasib, including in chemotherapy-resistant models.Elraglusib has also produced complete responses in a phase 1 trial in relapsed/refractory Ewing sarcoma, a paediatric cancer with no approved targeted therapies.To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [email protected]
This week, we have a conversation with Philip Brainin, CEO of Isomab, about restoring blood flow to the heart, and with RougeTx CEO Andrew Lightfoot, about developing a treatment for hereditary haemorrhagic telangiectasia (HHT).Times:03:34 Isomab25:29 RougeTxIsomabIsomab, a preclinical UK biotech, recently presented safety data at ESC recently that may not sound particularly exciting at first glance, but the implications for cardiovascular drug development could be significant.For decades, the field has been trying to stimulate new blood vessel growth to restore blood flow to the heart, but concerns that this could increase the risk of cancer or damage to the retina have been a major barrier.Isomab’s systematic review of more than 20 years of clinical trial data found no evidence of these long-held safety concerns, potentially removing a significant obstacle to developing an entirely new class of disease-modifying cardiovascular therapies.Isomab believes its approach could open up a new avenue for treating coronary artery disease. The company has a lead drug candidate in ISM-001, which selectively removes VEGF-A165b to restore the natural signalling balance that enables healthy vascularisation in the heart. VEGF-A165b was first identified in 2001 by David Bates, scientific founder of Isomab, and has since been validated in more than 100 publications from more than 80 independent laboratories worldwide.RougeTxRougeTx, launched recently with a $58m Series A financing to advance first-in-class therapies designed to restore vascular integrity by targeting pericyte dysfunction.RougeTx is developing novel therapies for diseases driven by vascular instability, with lead programme RTX-001 advancing towards first-in-human clinical development for hereditary haemorrhagic telangiectasia (HHT), a serious inherited bleeding disorder for which there are currently no approved therapies.RougeTx's periSCOPE platform is being used to identify additional opportunities across diseases associated with vascular instability. The company is built on more than two decades of research into the role of pericytes in maintaining blood vessel integrity.To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [email protected]
This week, we talk about mitochondria and obesity with Jon Rees, co-founder and CEO of MitoRx Therapeutics, and also have a chat with Apeximmune Therapeutics’ CEO and founder Li-Fen Lee, and senior director of biology Kan Lu, about a new breakthrough in shrinking tumours.Times:03:11 MitoRx Therapeutics25:06 Apeximmune TherapeuticsMitoRx TherapeuticsMitoRx Therapeutics is developing new treatments to restore healthy mitochondrial metabolism in patients living with high-risk obesity. Its first-in-class small molecule asset, MTRX31, targets the elimination of ectopic fat in people with metabolically unhealthy obesity, by restoring mitochondrial health rather than suppressing appetite.Preclinical data for MTRX31 has shown superior magnitude, quality and durability of weight loss compared with tirzepatide in an industry-standard preclinical model of obesity. MTRX31-driven weight loss does not involve lean mass loss, meaning basal metabolic rate is maintained – providing durable, healthy weight loss.The company recently presented new preclinical data at the EASD conference recently..Apeximmune TherapeuticsApeximmune Therapeutics, Inc. is an IND-stage biotechnology company in South San Francisco focused on developing novel immunotherapies for patients who do not respond to existing immune checkpoint inhibitors.The company applies proprietary computational target discovery to identify mechanistically distinct immune checkpoints with the potential to expand the reach of immuno-oncology. The company recently saw its research published in Nature with a piece entitled “PLA2G2D in tumour-draining lymph nodes regulates anti-tumour immunity.”The publication validated PLA2G2D as a novel and mechanistically distinct immune checkpoint capable of addressing resistance to anti-PD-1 therapy. The publication represents the convergence of two independent research programmes – one led by Apeximmune, the other by researchers at Erasmus University Medical Center in Rotterdam, the Netherlands – that arrived at the same target using different approaches. To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [email protected]
loading
Comments